The Australian government is beginning the second phase of a reform program intended to reduce the regulatory burden on drug and medical device companies when carrying out product recalls while retaining a “strong emphasis on public safety.”
Australia Cuts Regulatory Burden Of Product Recalls
The Therapeutic Goods Administration says it has made a series of improvements in areas such as the recall and stakeholder communication process, reporting requirements, and the agency’s guidance materials.
